Osmol Therapeutics Information
Contact top employees from
Osmol Therapeutics
Summary
Osmol Therapeutics is developing OSM-0205, our lead investigational candidate, to address the urgent need of patients faced with the challenges of chemotherapy-induced peripheral neuropathy (CIPN) and...Show more
Industries
Biotechnology
Headquarters Location
Employees Size
1-10 employees
Specialties
chemotherapy-induced peripheral neuropathy, CIPN, chemotherapy-induced cognitive impairment, CICI, OSM-0205, breast cancer, intracellular calcium, taxanes, taxane-based therapy, cancer treatment, chemotherapy, central nervous system, chemo brain, calcium surge, neuronal damage
Founded
2016
Employees Turnover 3 quarter 2025
Length of Employment
Employee tenure at Osmol Therapeutics shows a diverse range of experience levels:
25% have been with the company for less than 1 year25% for 1–2 years25% for 3–4 years25% for 5–7 yearsContact top employees from
Osmol Therapeutics
